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Abstract
Endometrial stromal sarcomas (ESS) are often underpinned by recurrent chromosomal 
translocations resulting in the fusion of genes involved in epigenetic regulation. To date, only 
YWHAE-NUTM2 rearrangements are associated with distinctive high-grade morphology and 
aggressive clinical behavior. We identified 3 ESS morphologically mimicking myxoid 
leiomyosarcoma of the uterus and sought to describe their unique histopathologic features and 
identify genetic alterations using next-generation sequencing. All cases displayed predominantly 
spindled cells associated with abundant myxoid stroma and brisk mitotic activity. Tumors involved 
the endometrium and demonstrated tongue-like myometrial infiltration. All 3 were associated with 
an aggressive clinical course, including multisite bony metastases in 1 patient, progressive 
peritoneal disease after chemotherapy in another and metastases to the lung and skin in the last 
patient. All 3 ESS were found to harbor ZC3H7B-BCOR gene fusions by targeted sequencing and 
fluorescence in situ hybridization. On the basis of the review of these cases, we find that ESS with 
ZC3H7B-BCOR fusion constitutes a novel type of high-grade ESS and shares significant 
morphologic overlap with myxoid leiomyosarcoma.
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Introduction
Endometrial stromal sarcomas (ESS) account for 1% of all uterine malignancies and 15% of 
malignant mesenchymal neoplasms of the uterus.1 Since the foundational descriptions 
provided by Norris and Taylor in 1966, the classification of ESS has undergone several 
modifications.2–5 Currently, the 2014 World Health Organization categorizes ESS into low-
grade ESS (LG-ESS), high-grade ESS (HG-ESS), and undifferentiated uterine sarcoma 
(UUS).6
Morphologically, LG-ESS resembles proliferative-type endometrial stroma.2 It is composed 
of monotonous populations of small cells with round, oval to fusiform nuclei concentrically 
arranged around thin-walled spiral arterioles.2,7,8 Tongue-like infiltration of the myometrium 
and “worm-like” plugs in the uterine vessels are characteristic findings. Collagen plaques, 
cholesterol clefts, and foamy histiocytes may also be present.8 Mitotic activity is usually 
<5/10 high power fields (HPF); however higher mitotic indices may be encountered.7–9 A 
myriad of variant histologic features have been described, including smooth muscle, 
glandular, sex-cord, and rhabdomyoblastic differentiation, as well as myxoid/fibromyxoid, 
fibrous, pseudopapillary, and epithelioid change.7,10–21 By immunohistochemistry, LG-ESS 
is positive for estrogen receptor (ER), progesterone receptor (PR), and CD10.22–24 
Approximately half of LG-ESS harbor t(7;17) chromosomal translocations resulting in 
JAZF1-SUZ12 gene fusion.25–27 Other gene fusions, including JAZF1-PHF128, EPC1-
PHF128, MEAF6-PHF1,29,30, and MBTD1-CXorf6731 are rare. While PHF1 rearrangements 
have been reportedly associated with sex-cord differentiation32, other gene fusions found in 
LG-ESS have not been linked with variant morphologic features. JAZF1-SUZ12 gene 
fusions are only extraordinarily encountered in the fibromyxoid variant.13 LG-ESS tend to 
be indolent tumors with 5-year survival rates >90% for low-stage disease.7,33
UUS is considered a diagnosis of exclusion and harbors little histologic resemblance to 
normal endometrial stroma, particularly when the nuclei are pleomorphic.6 The tumor cells 
in UUS of the pleomorphic type display severe nuclear atypia, brisk mitotic activity, and 
necrosis. Most reported UUS exhibit complex karyotypes without defining genetic 
rearrangements and portend a dismal prognosis.34–36
The term, HG-ESS, was recently reintroduced into the classification of endometrial stromal 
tumors based on the discovery of the t(10;17) translocation resulting in fusion of YWHAE 
and NUTM2 genes. YWHAE-rearranged HG-ESS is characterized by a proliferation of 
round cells with nested or pseudoglandular patterns separated by thin-walled vessels. The 
nuclei of the round cells are larger and display more irregular nuclear contours compared to 
LG-ESS and share morphologic overlap with UUS of uniform type.26,37 Mitotic activity is 
>10/10 HPF, and necrosis is common. Approximately half of reported cases are admixed 
with a low-grade fibromyxoid component which expresses ER, PR, and CD10. In contrast, 
the round cell component is usually negative for these markers, but is often strongly and 
diffusely positive for cyclin D1 and CD117.38,39 YWHAE-rearranged HG-ESS bear an 
intermediate prognosis, between LG-ESS and UUS.37
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Although rare, morphologically HG-ESS and UUS of uniform type that lack YWHAE-
rearrangements exist and likely harbor genetic alterations that have yet to be characterized.40 
Here we describe a novel form of high-grade ESS exhibiting aggressive clinical behavior as 
well as histologic and immunophenotypic features mimicking myxoid leiomyosarcoma 
(LMS). In this study, we detail the unusual and distinct morphology of this tumor. We 
performed next-generation sequencing and fluorescence in situ hybridization to uncover 
genetic alterations that underpin this tumor type.
Materials and methods
Case selection
From 2013 to 2016, 3 uterine sarcomas displaying morphologic overlap between ESS and 
myxoid LMS were identified on the Gynecologic Pathology Consultation Service at 
Memorial Sloan Kettering Cancer Center, New York, NY. Available hematoxylin and eosin 
stained and immunohistochemical-stained slides from the original institutions were reviewed 
to delineate the morphologic and immunophenotypic features. Clinical data were reviewed 
for demographics, presentation, treatment, and outcome.
Next Generation Sequencing
For case 1, genomic alterations were profiled using MSK-IMPACT (Memorial Sloan 
Kettering – Integrated Mutation Profiling of Actionable Cancer Targets)41, a custom hybrid 
capture-based sequencing assay, performed on formalin-fixed paraffin-embedded (FFPE) 
tumor tissue. Custom oligonucleotide probes were designed to capture all exons and selected 
regulatory regions and introns of 410 key cancer genes. Captured pools from paired normal 
and tumor samples were sequenced on an Illumina HiSeq2500, with a minimum depth of 
coverage of 100X. Variants were called with reference to the patient’s matched normal 
sample, to assure they were all somatic in nature. Tumor DNA of case 2 was subjected to 
Foundation One sequencing assay (http://www.foundationone.com), which targeted the 
exons of 315 cancer-related genes and introns from 28 genes often rearranged or altered in 
cancer on an Illumina HiSeq2000. The tumor from case 3 was analyzed using the MSK-
Solid Fusion assay, a targeted RNA-based panel that utilizes the Archer Anchored Multiplex 
PCR (AMP™) technology42 and next-generation sequencing to detect genes fusions in solid 
tumor and sarcoma samples. Unidirectional gene specific primers were designed to target 
specific exons in 35 genes known to be involved in chromosomal rearrangements, RNA was 
extracted from tumor FFPE material followed by cDNA synthesis and library preparation. 
Final targeted amplicons were sequenced on an Illumina MiSeq. Data was analyzed using 
the Archer™ Software (version 4.0.10).
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) was performed on interphase nuclei from FFPE 4 
μm tissue sections from cases 1 and 2 as previously described.43 Custom probes using 
bacterial artificial chromosomes (BAC) covering and flanking the BCOR gene and ZC3H7B 
gene were chosen according to the UCSC genome browser (http://genome.ucsc.edu). The 
BAC clones were retrieved from BACPAC sources of the Children’s Hospital of Oakland 
Research Institute (CHORI) (Oakland, CA) (http://bacpac.chori.org). The DNA from 
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individual BACs were isolated according to manufacturer’s recommendations, labelled with 
different fluorochromes in a nick translation reaction, denatured, and then hybridized to 
pretreated slides. The slides were then incubated, washed, and mounted with DAPI in an 
anti-fade solution, as previously reported.44 The genomic location of each BAC set was 
confirmed by hybridizing them to normal metaphase chromosomes. Using a Zeiss 
fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), 200 successive nuclei 
were examined, controlled by Isis 5 software (Metasystems). A positive score was given 
when at least 20% of the nuclei displayed a break-apart signal. Nuclei with incomplete sets 
of signals were omitted from interpretation.
Results
Clinicopathologic Features
Case 1—A 36-year-old gravida 2 para 1 woman with a history of fibroid uterus presented 
with increasing pelvic pain. An ultrasound revealed that her fibroids had increased in size 
compared to 2 years prior, and she underwent a myomectomy with morcellation and removal 
of tissue measuring up to 15 cm in aggregate. A pathologic diagnosis of sarcoma was 
rendered, and a completion hysterectomy, bilateral salpingo-oophorectomy, omentectomy, 
and debulking were subsequently performed 1 month later. Intraoperatively, a large 
heterogeneous mass attached to the uterus as well as extensive infiltration of the mesentery 
were found. All gross disease was completely resected.
On histopathologic examination, a 10 cm gray-white hemorrhagic tumor was present in the 
uterine fundus with extension into the cervix and metastases to the right adnexae and 
omentum. The tumor was predominantly spindled with minor epithelioid areas, had focal 
fascicular architecture, and extensive myxoid change. The cells displayed round to oval 
nuclei with irregular nuclear contours, inconspicuous nucleoli, and hyperchromatic to clear 
chromatin (Figure 1). The tumor edge displayed broad pushing and infiltrative growth 
patterns, with the latter predominating. There were delicate thin-walled capillaries, although 
tumor cells did not whorl around them (Figure 2). Mitotic activity was 3–4/10 HPF and 
reached 10/10 HPF in 1 slide. Ki-67 proliferation index was 20%. The tumor was diffusely 
positive for CD10, ER, and PR, and focally positive for SMA, while negative for desmin and 
ALK1. “Invasive endometrial stromal neoplasm, with features between low-grade and high-
grade” was diagnosed at the original institution. Two independent external consultations 
rendered a diagnosis of myxoid LMS.
The patient received postresection whole-pelvic radiation and was treated with an aromatase 
inhibitor. Twenty-two months after the myomectomy, the patient developed peritoneal 
disease, implants on the surface of the liver, and a lytic lesion of the sacrum. She was treated 
with a change in the aromatase inhibitor and stereotactic radiosurgery to the sacral lesion. 
Six months later, she developed multisite bony metastases, increasing peritoneal disease and 
enlarged pelvic lymph nodes. Treatment was changed to cytotoxic chemotherapy with 
gemcitabine plus docetaxel. There was progression of disease after 2 cycles of therapy. The 
patient was then treated with doxorubicin.
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Case 2—A 48-year-old gravida 3 para 1 woman with a history of fibroid uterus noticed 
increased vaginal bleeding and pelvic pain for 5 months despite leuprolide therapy. She 
underwent a planned laparoscopic hysterectomy for presumed fibroids. In the operating 
room, significant bleeding was noted due to gross rupture of a large pelvic mass involving 
the anterior uterus, left adnexa, broad ligament, and surrounding structures. The procedure 
was converted to open total abdominal hysterectomy, bilateral salpingo-oophorectomy, and 
debulking surgery.
Histopathologic examination revealed a 12 cm yellow-tan exophytic tumor in the fundus, 
transmurally involving the uterine wall, as well as the left adnexa, parametrium, pelvic side 
wall, small bowel, and a para-aortic lymph node. The tumor was composed of spindled cells 
with areas of fascicular architecture and myxoid change (Figure 3). The tumor was focally 
hypercellular in the less myxoid areas and demonstrated tongue-like myometrial invasion 
with worm-like plugs of tumor within blood vessels. The tumor nuclei displayed irregular 
nuclear contours, inconspicuous nuclei, and hyperchromatic to clear chromatin. Abundant 
mitotic activity (>30/10HPF), atypical mitotic figures, and thin-walled vessels were present, 
but lacked whorling of tumor cells (Figure 4). By immunohistochemistry, the tumor cells 
were diffusely positive for CD10, focally positive for desmin and negative for ER, PR, 
caldesmon, SMA, ALK1, cyclin D1, inhibin, S100, GFAP, and AE1/AE3. Alcian Blue was 
diffusely positive. While the tumor was noted to have features resembling both ESS and 
myxoid LMS, a diagnosis of UUS was ultimately rendered at the original institution.
CT imaging performed 2 months after resection showed recurrent pelvic masses. She was 
treated with doxorubicin plus ifosfamide, with at best stable disease on follow-up imaging.
Case 3—A 44-year-old gravida 4 para 1 woman presented with vaginal bleeding. She had a 
cervical polypectomy and endometrial curettings which revealed fragments of sarcoma most 
consistent with LMS. Two external consultations from 2 separate institutions diagnosed 
myxoid LMS. The patient then had a hysterectomy, bilateral salpingo-oophorectomy, and 
hypogastric lymph node excised.
On histopathologic examination, there was a 2.5 cm tumor in the uterine corpus and 0.7 cm 
nodule in the cervix, diagnosed as a myxoid LMS. The tumor was composed of spindled 
cells in a background of myxoid stroma (Figures 5 and 6). There were both tongue-like and 
infiltrative patterns of invasion into the myometrium. The nuclei were enlarged, had irregular 
nuclear contours, hyperchromasia, coarse chromatin, and inconspicuous nucleoli. Scattered 
thin walled blood vessels were present. The mitotic count was 10/10 HPF. Worm-like 
lymphovascular invasion was also present.
The patient received gemcitabine and docetaxel. Ten months after the initial diagnosis, the 
patient developed multiple lung metastases. A fine-needle aspiration biopsy was performed 
revealing a spindle cell neoplasm, favored to be metastatic myxoid LMS from the uterine 
primary. The tumor was positive for CD10, SMA, and negative for desmin, caldesmon, ER, 
PR, CD34, and S100. She was treated briefly with single agent gemcitabine but stopped 
treatment due to poor tolerance. Over the next 2 years, some lung lesions demonstrated a 
slow increase in size while others remained stable or regressed. Radiofrequency ablation was 
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given to several of the lung lesions. Two years later, the patient had progression of disease 
involving thoracic and pelvic lymph nodes, while the small lung metastases remained stable. 
She was treated with liposomal doxorubicin and had a minor radiographic response. One 
year later, the right upper lobe mass grew to obstruct the right mainstem bronchus, and she 
was treated with palliative radiation to the mass. Further progression of disease in the pelvis 
involved the sacral plexus, and the patient developed a large, symptomatic deep venous 
thrombosis, treated with a venous stent and anticoagulation. Subsequently, the patient 
developed a non healing skin lesion involving the right temple. A biopsy demonstrated a 
malignant spindle cell neoplasm showing focal weak staining for S100 and diffuse positivity 
for p75-NGFR and vimentin, while lacking MelanA, tyrosinase, and SMA expression. On 
the basis of the tumor location and immunophenotype, a malignant spindle cell melanoma 
was diagnosed at the original institution. Additional stains performed at our institution 
showed diffuse staining for cyclin D1, focal staining for SMA and SOX10 (focal weak), but 
no desmin or BRAFV600E staining. This immunoprofile prompted comparison with the 
prior uterine and lung masses. On the basis of morphologic similarity among all three 
tumors, a cutaneous metastasis of the patient’s known widely metastatic uterine sarcoma 
was ultimately confirmed at our institution.
Next-Generation Sequencing
Case 1 was subjected to MSK-IMPACT sequencing at a median sequencing depth of 
coverage of 924X and was found to have an in frame fusion between ZC3H7B exon 10 
(NM_017590) and BCOR exon 7 (NM_001123385) (t(X;22)(p11.4;q13.2)(chrX:c.
3146::chr22:c.1525)) (Figure 7). No somatic mutations, copy number aberrations, or other 
structural rearrangements were identified. Genomic testing of case 2 by Foundation One also 
revealed a ZC3H7B-BCOR fusion in addition to amplification of CDK4, MDM2, FRS2 
genes, HDAC4-HABP2 fusion, and seven variants of unknown significance. Case 3 was 
analyzed using the MSK-Solid Fusion panel. This also revealed an in-frame fusion between 
ZC3H7B exon 10 (NM_017590) and BCOR exon 7 (NM_001123385).
Fluorescence In Situ Hybridization
In cases 1 and 2, FISH confirmed gene rearrangements in both ZC3H7B and BCOR (Figure 
8).43 FISH for YWHAE and JAZF1 rearrangements were also performed on case 2 at the 
original institution and were both negative by report.
Discussion
In this report, we describe for the first time the association of ZC3H7B-BCOR fusion 
resulting from t(X;22)(p11.4;q13.2) in tumors with extensive myxoid change and focal 
fascicular architecture mimicking myxoid LMS and thus representing a potential diagnostic 
pitfall. Two cases were misdiagnosed as myxoid LMS, including 1 case in which the unusual 
skin recurrence and immunophenotype (limited S100 and SOX10 positivity and diffuse p75-
NGFR positivity) also misled to a new primary diagnosis of malignant melanoma. In another 
case, myxoid LMS was considered in the differential diagnosis. Detection of the ZC3H7B-
BCOR fusion prompted a re-review of the histopathology of the uterine primary and 
recurrences, and in all cases, a diagnosis of ESS with extensive myxoid features was 
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ultimately rendered based on the molecular genetic findings, involvement of the 
endometrium, and characteristic pattern of myometrial invasion.
ZC3H7B-BCOR fusion has been previously reported in ESS by Panagopoulos et al. in 
2013.45 In their series, both tumors were composed of non pleomorphic spindled cells, and 
although not explicitly mentioned, one of them harbored a myxoid quality in the figure 
presented. One case had minimal mitotic activity (0 to 1/10 HPF) and expressed CD10, ER, 
and PR. However, the other had brisk mitotic activity (26/10 HPF) and expressed CD10, but 
lacked ER and PR staining. Both patients presented with high-stage disease, in which tumors 
metastasized to the distal ureter and bowel, respectively. No recurrences were documented at 
the time of publication; however the follow-up period was not specified. The morphologic 
and clinical features parallel those observed in our study. In a separate study by Lee et al., 
karyotypic data available in 12 HG-ESS included 2 cases demonstrating t(X;22)
(p11.4;q13.2). Although this translocation was not characterized in their study and the 
morphologic description of these 2 cases was not available in their report, both tumors likely 
harbor ZC3H7B-BCOR rearrangements based on their cytogenetic profiles.34,45
The morphologic distinction of BCOR-rearranged ESS from myxoid LMS poses an 
important diagnostic challenge. Myxoid LMS can also exhibit spindled cells with fascicular 
architecture, nonpleomorphic nuclei and minimal mitotic activity.46–48 In contrast to myxoid 
LMS, however, our ESS tumors lacked long fascicles, thick-walled blood vessels, dense 
eosinophilic cytoplasm and cigar-shaped nuclei with blunted ends, features which typify 
smooth muscle neoplasms. Two tumors in our series were SMA positive, and 1 was focally 
desmin positive. The presence of desmin staining, however, does not exclude a diagnosis of 
ESS, as desmin positivity has been reported in up to 50% of ESS, especially those that 
demonstrate smooth muscle differentiation.22,23 In addition, all 3 of our cases demonstrated 
lymph node involvement, 2 radiologically and 1 confirmed by biopsy. Although lymph node 
metastases in uterine sarcomas are overall rare, lymph node involvement is more frequently 
seen in ESS than in LMS.49–51 All 3 patients were also alive with disease 37, 13, and 80 
months, respectively, at last follow-up from the time of diagnosis, similar to the clinical 
course of YWHAE-rearranged ESS37 rather than LMS which has a reported 66% 5-year 
survival rate.50
Given some of the overlapping morphologic features with myxoid LMS, we speculate that a 
subset of myxoid LMS may actually represent BCOR-rearranged ESS. Although it is 
acknowledged that CD10 is not an entirely specific marker for endometrial stromal 
differentiation, it is also worthwhile mentioning that in 2 of the largest series of myxoid 
LMS, 10/18 (55%) and 7/18 (39%) of tumors showed moderate to strong (2+ to 3+) staining 
for CD10, similar to our ESS.48 The investigation for BCOR and ZC3H7B rearrangements 
in histologically classified myxoid LMS would be an interesting endeavour and merits 
further study.
Kurihara and colleagues was the first to emphasize the distinction between uniform and 
pleomorphic types of UUS. In their 7 cases classified as UUS of uniform type, 2 were 
described as having diffuse fibromyxoid features and fascicular architecture. It is, therefore, 
possible that these 2 cases of uniform-type UUS described by Kurihara et al., and even some 
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of the cases previously described as fibromyxosarcoma in the uterus, may also represent 
BCOR-rearranged ESS.26,52
BCOR (BCL-6 interacting corepressor) can bind to the POZ domain of BCL-6, potentiating 
its function, interact with histone deacetylases, or form chromatin modifying complexes 
which along with the polycomb repressive complex 1 enhance transcriptional 
repression.53–55 BCOR has also been shown to affect embryonic and mesenchymal stem cell 
differentiation56,57, hematolymphoid development 58,59, and determination of laterality.60,61 
While germline mutations in BCOR result in the syndromic diseases, oculo-facio-cardio-
dental syndrome and Lenz microphthalmia,62 somatic BCOR mutations have been reported 
in various hematolymphoid malignancies63–68, retinoblastoma69, medulloblastoma 70, 
central nervous system primitive neuroectodermal tumors71, rhabdomyosarcoma,72 and clear 
cell sarcoma of the kidney.73–76
BCOR rearrangements are not limited to ESS. Recently, Antonescu et al. has reported 
ZC3H7B–BCOR, MEAF6–PHF1 and EPC1–PHF1 fusions in a subset of ossifying 
fibromyxoid tumors (OFMT)43; these genetic rearrangements have also been reported in 
ESS.28,29,45 Notably, ZC3H7B-BCOR rearrangements were identified in 2 OFMT, both of 
which displayed malignant features and were S100-negative.43 Rearrangements in BCOR 
have also been identified in undifferentiated small blue round cell tumors, undifferentiated 
spindle cell sarcomas that lack EWS rearrangements,77–79 and a single case of acute 
promyelocytic leukemia.80 The presence of BCOR rearrangements across diverse tumor 
types suggests the likely role of BCOR driving tumourigenesis. It is noteworthy that SUZ12, 
PHF1, and MBTD1 are also members of the polycomb repressive complex family, and 
EPC1 and MEAF2 function to alter acetylation of histone proteins.3,28,29 It appears that all 
genes found to be rearranged in ESS have a unifying role in epigenetic regulation, either 
through polycomb-mediated gene silencing or post-translational covalent modification of 
histone proteins.
Less is known about ZC3H7B (also known as RoXaN). It contains several domains 
(tetratricopeptide repeats, zinc finger motifs, LD motif) responsible for coordinating protein-
protein and protein-nuclei acid interactions. It is thought to have roles in regulating 
translation and nucleocytoplasmic localization.45,81,82
In addition to myxoid LMS, a number of other entities enter the differential diagnosis for 
cases with a histologic appearance like the 3 ESS described here. An argument can be made 
that the morphology in the present 3 cases resemble the myxoid/fibromyxoid variants of LG-
ESS reported in the literature.16–19,52,83,84 Our 2 cases, however, had mitotic activity 
>10/10HPF (at least focally), displayed nuclear features that exceeded the level of cytologic 
atypia seen in LG-ESS and had no areas with prototypical LG-ESS histology. Although 
OFMT and our current cases of BCOR-rearranged ESS share some morphologic and 
molecular similarities, we still consider these 2 tumors as distinct entities. OFMT tend to 
occur in the deep soft tissues, is well circumscribed, and typically has a shell of lamellar or 
woven bone.43 Inflammatory myofibroblastic tumors (IMT) may be myxoid and thus are 
also in the differential diagnosis, but are typically positive for ALK1 and lack the infiltrative 
pattern characteristic of ESS.
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Immunohistochemistry has long played an important role in the distinction between 
endometrial stromal tumors and smooth muscle neoplasia. A panel of CD10 and 2 smooth 
muscle markers including desmin has been recommended in the differential diagnosis of a 
conventional LG-ESS or endometrial stromal nodule and a highly cellular leiomyoma. The 
utility of immunohistochemistry in assessing uterine mesenchymal tumors that exhibit 
predominant variant morphologic features particularly of the myxoid nature currently 
appears less informative as there is extensive overlap of CD10, desmin, actin, h-caldesmon, 
ER, and PR among ESS, UUS, LMS, and IMT, all of which may show myxoid change. 
While cyclin D1 and ALK expression may suggest YWHAE-rearranged HG-ESS and IMT, 
respectively, robust immunohistochemical markers identifying other variants of ESS, 
including BCOR-rearranged HG-ESS, UUS, or myxoid LMS are currently lacking. 
Furthermore, case 3 reported herein showed diffuse cyclin D1 expression, further 
complicating the differential diagnosis with YWHAE-rearranged HG-ESS. All 3 of our 
BCOR-rearranged ESS showed strong and diffuse CD10 expression with limited desmin or 
SMA staining. This immunoprofile of a uterine sarcoma bearing resemblance to myxoid 
LMS, but extending from the endometrium and displaying tongue-like myometrial invasion 
should prompt molecular testing such as FISH or RNA sequencing. Akin to hematologic 
malignancies and soft tissue sarcomas, detection of specific genetic alterations by these 
methods will likely become pivotal in refining the diagnosis and classification of uterine 
mesenchymal tumors that display ambiguous morphologic and immunophenotypic features.
In summary, we highlight the histomorphologic features of BCOR-rearranged ESS, a 
distinct entity that should be considered in the differential diagnosis of myxoid uterine 
mesenchymal tumors. Given that the cytomorphologic features exceed that allowable for 
LG-ESS, in conjunction with the aggressive clinical behaviour suggested in our study and at 
least one other, BCOR-rearranged ESS are best classified as a form of HG-ESS distinct from 
YWHAE-rearranged ESS. With increasing awareness of this tumor type and its morphologic 
differential diagnosis, combined with the increasing availability of next-generation 
sequencing, it is likely that such cases will be more readily detected in the near future.
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Figure 1. Histopathology of t(X;22) ZC3H7B-BCOR ESS, case 1
The tumor was spindled with epithelioid areas, showed focal fascicular architecture and 
extensive myxoid change. The tumor cell nuclei were enlarged, with irregular nuclear 
contours and displayed clear to hyperchromatic chromatin.
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Figure 2. Additional histologic features of ESS with ZC3H7B-BCOR translocation, case 1
(A) Predominantly spindled neoplasm with myxoid features and a pushing border; (B) Focal 
fascicular architecture and thin-walled blood vessels; (C) Areas with more prominent 
myxoid stroma; (D) Involvement of the uterine cervix; (E) CD10 was strongly positive; (F) 
Desmin was negative (positive staining seen in background myometrium).
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Figure 3. Histopathology of t(X;22) ZC3H7B-BCOR ESS, case 2
The tumor was composed of spindled and epithelioid cells with extensive myxoid changes. 
The tumor cell nuclei were monotonous, and the chromatin varied from pale/clear to 
hyperchromatic.
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Figure 4. Additional histologic features of ESS with ZC3H7B-BCOR translocation, case 2
(A) Tongue-like myoinvasion and worm-like plugs of the uterine vessels; (B) Spindled cells 
embedded in myxoid stroma; (C) Cytologic atypia with enlarged nuclei, irregular nuclear 
contours and hyperchromatic to pale/clear chromatin; (D) Collagen plaques; (E) Thin-walled 
blood vessels; (F) More cellular areas were present with less myxoid stroma.
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Figure 5. Histopathology of t(X;22) ZC3H7B-BCOR ESS, case 3
The tumor was composed of spindled cells in a background diffuse myxoid stroma. The 
tumor cell nuclei were enlarged, had irregular nuclear contours, coarse chromatin and some 
had conspicuous nucleoli. Mitoses were up to 10/10 high power fields.
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Figure 6. Additional histologic features of ESS with ZC3H7B-BCOR translocation, case 3
(A–B) The tumor was composed of spindled cells in a myxoid stroma; (C) Worm-like plugs 
of tumor were seen in blood vessels; (D) Alcian blue pH 2.5 was positive; (E) CD10 was 
strongly and diffusely positive; (F) Caldesmon was negative (positive staining seen in 
background myometrium).
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Figure 7. Pictorial representation of the ZC3H7B-BCOR translocation on Integrated Genome 
Viewer
Each bar is a single sequenced read with the top panel displaying data from tumor sample 
and bottom panel displaying its matched normal sample. The reads are sorted to highlight 
read pairs with discordant read mapping on the top for each sample. As evident, one set of 
reads maps to ZC3H7B on chromosome 22 while the their corresponding paired end reads 
map to BCOR on the X chromosome, supporting the presence of a somatic fusion involving 
both genes.
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Figure 8. Fluorescence in-situ hybridization confirmation of BCOR and ZC3H7B rearrangements 
in ESS case 1
Break-apart assays for BCOR and ZC3H7B both show split signals (arrows, red probe 
centromeric, green probe telomeric) confirming rearrangements in both genes.
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